Everything below concerns PT-141. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
=== EC 1.13.12 With incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases) === EC 1.13.12.1: arginine 2-monooxygenase EC 1.13.12.2: lysine 2-monooxygenase EC 1.13.12.3: tryptophan 2-monooxygenase EC 1.13.12.4: lactate 2-monooxygenase EC 1.13.12.5: Renilla-type luciferase EC 1.13.12.6: Cypridina-luciferin 2-monooxygenase EC 1.13.12.7: firefly luciferase EC 1.13.12.8: Watasenia-luciferin 2-monooxygenase EC 1.13.12.9: phenylalanine 2-monooxygenase EC 1.13.12.10: Reaction covered by EC 1.14.13.59, L-lysine 6-monooxygenase (NADPH) EC n1.13.12.11: The activity is due to EC 1.14.13.8, flavin-containing monooxygenase EC 1.13.12.12: transferred to EC 1.13.11.67, 8-apo-β-carotenoid 14′,13′-cleaving dioxygenase EC 1.13.12.13: Oplophorus-luciferin 2-monooxygenase EC 1.13.12.14: Now EC 1.14.13.122, chlorophyllide-a oxygenase EC 1.13.12.15: 3,4-dihydroxyphenylalanine oxidative deaminase EC 1.13.12.16: nitronate monooxygenase EC 1.13.12.17: dichloroarcyriaflavin A synthase EC 1.13.12.18: dinoflagellate luciferase EC 1.13.12.19: 2-oxoglutarate dioxygenase (ethene-forming) EC 1.13.12.20: noranthrone monooxygenase EC 1.13.12.21: tetracenomycin-F1 monooxygenase EC 1.13.12.22: deoxynogalonate monooxygenase EC 1.13.12.23: 4-hydroxy-3-prenylbenzoate synthase EC 1.13.12.24: calcium-regulated photoprotein
== Thermodynamics == Self-assembly is an equilibrium process, i.e. the individual and assembled components exist in equilibrium. In addition, the flexibility and the lower free energy conformation is usually a result of a weaker intermolecular force between self-assembled moieties and is essentially enthalpic in nature. The thermodynamics of the self-assembly process can be represented by a simple Gibbs free energy equation:
=== Differential diagnosis === Other conditions that can cause bluish skin include argyria, sulfhemoglobinemia, heart failure, amiodarone-induced bluish skin pigmentation and acrodermatitis enteropathica.
Sources: en.wikipedia.org
=== Preparation of samples === Microtox can be applied to a variety of matrices including drinking water, stormwater runoff, effluent, industrial discharges, soils and sediments. Most samples do not require special preparation before testing besides adjusting the salinity to 2%. However, samples that have certain characteristics, such as high turbidity levels, may require special preparation. If samples require a salinity adjustment to lower the salinity, this can be accomplished by adding an appropriate amount of Microtox Osmotic Adjusting Solution to dilute the sample. For example, adding 0.1 mL of MOAS to 1 mL of sample would result in a dilution of 90.9% of the original concentration. If a greater salinity is required, this can be accomplished by dissolving solid sodium chloride in the sample to achieve a final salinity of 2% for the protection of Allivibrio fischeri. Highly turbid samples that contain particulate matter will be required to settle before the test can be conducted. Particulate matter in the sample can interfere with bioluminescence by absorbing light and give misleading test results. Interference of luminescence can also occur with samples which are highly colored (particularly red, brown or black). It may be necessary to centrifuge samples to obtain an acceptable clarity for the test. If samples contain chlorine, this may alter the toxicity to Allivibrio fischeri and also give misleading results. The samples can be de-chlorinated using a sodium thiosulphate and deionized water solution that does not affect test results.
Levomethadone, sold under the brand name L-Polamidon among others, is a synthetic opioid analgesic and antitussive which is marketed in Europe and is used for pain management and in opioid maintenance therapy. In addition to being used as a pharmaceutical drug itself, levomethadone is also the main therapeutic component of methadone, which is a racemic mixture of levomethadone (R-methadone) and dextromethadone (S-methadone). Levomethadone is used for narcotic maintenance in place of, or in some cases alongside as an alternative, to racemic methadone, owing to concern that the cardiotoxic and QT-prolonging action of racemic methadone might be primarily caused by dextromethadone.
=== Pharmacokinetics === KNX-100 has improved pharmacokinetics relative to oxytocin, such as enhanced oral bioavailability, blood–brain barrier permeability, and metabolic stability, and may overcome the pharmacokinetic and efficacy limitations of oxytocin.
=== Pre-cigarette === Texts on the harmful effects of smoking tobacco were recorded in the Timbuktu manuscripts. James I wrote a book that denounced tobacco smoking as: "loathsome to the eye, hateful to the nose, harmful to the brain, dangerous to the lungs". Pipe smoking gradually became generally accepted as a cause of mouth cancers following work done in the 1700s. "An association between a variety of cancers and tobacco use was repeatedly observed from the late 1800s into the early 1920s." Gideon Lincecum, an American naturalist and practitioner of botanical medicine, wrote in the early 19th century on tobacco: "This poisonous plant has been used a great deal as a medicine by the old school faculty, and thousands have been slain by it. ... It is a very dangerous article, and use it as you will, it always diminishes the vital energies in exact proportion to the quantity used – it may be slowly, but it is very sure." The 1880s invention of automated cigarette-making machinery in the American South made it possible to mass-produce cigarettes at low cost, and smoking became common. This led to a backlash and a tobacco prohibition movement, which challenged tobacco use as harmful and brought about some bans on tobacco sale and use. In 1912, American Dr. Isaac Adler was the first to strongly suggest that lung cancer is related to smoking. In 1924, economist Irving Fisher wrote an anti-smoking article for Reader's Digest which said "tobacco lowers the whole tone of the body and decreases its vital power and resistance ...
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.